On June 26, 2024, the FDA issued new draft guidance describing the format and content, medical products, clinical studies, timing, and process for submitting diversity action plans. Likewise, the criteria and process by which the FDA will evaluate sponsors’ requests for exemption from this requirement. This guidance is a response to the FDORA Act… Continue reading 2024 FDA Draft Guidance on Diversity Action Plans: Enhancing Inclusion in Clinical Studies